Clinical Trial: A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07585747) titled 'A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide' on April 13.

Brief Summary: Evaluate the efficacy and safety of orelabrutinib, tafasitamab, and lenalidomide in the first-line treatment of patients with follicular lymphoma.

Study Start Date: April 15

Study Type: INTERVENTIONAL

Condition: Follicular Lymphoma

Intervention: DRUG: Orelabrutinib

Orelabrutinib 150 mg orally once daily on Days 1-28 of each 28-day cycle during induction therapy and maintenance therapy.

DRUG: Tafasitamab

Tafasitamab 12 mg/kg administered by intravenous infusion on Days 1, 4, 8, 15, and 22 in Cycl...